These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Liguzinediol Enhances the Inotropic Effect of Rat Hearts via Inhibition of Protein Phosphatase (PP1 and PP2A) Activities. Li S; Huang H; Zhang M; Wang W; Xue S; Gao Y; Xie M; Chen K; Liu F; Chen L J Cardiovasc Pharmacol; 2017 Apr; 69(4):236-244. PubMed ID: 28134629 [TBL] [Abstract][Full Text] [Related]
3. Prolactin-releasing peptide effects in the rat brain are mediated through the Neuropeptide FF receptor. Ma L; MacTavish D; Simonin F; Bourguignon JJ; Watanabe T; Jhamandas JH Eur J Neurosci; 2009 Oct; 30(8):1585-93. PubMed ID: 19821834 [TBL] [Abstract][Full Text] [Related]
4. Stimulation and inhibition of prolactin release by prolactin-releasing Peptide in rat anterior pituitary cell aggregates. Swinnen E; Boussemaere M; Denef C J Neuroendocrinol; 2005 Jun; 17(6):379-86. PubMed ID: 15929743 [TBL] [Abstract][Full Text] [Related]
5. Biological properties of prolactin-releasing peptide analogs with a modified aromatic ring of a C-terminal phenylalanine amide. Maletínská L; Spolcová A; Maixnerová J; Blechová M; Zelezná B Peptides; 2011 Sep; 32(9):1887-92. PubMed ID: 21872625 [TBL] [Abstract][Full Text] [Related]
6. Regulation of the PRL promoter by Akt through cAMP response element binding protein. Hayakawa J; Ohmichi M; Tasaka K; Kanda Y; Adachi K; Nishio Y; Hisamoto K; Mabuchi S; Hinuma S; Murata Y Endocrinology; 2002 Jan; 143(1):13-22. PubMed ID: 11751586 [TBL] [Abstract][Full Text] [Related]
7. Characterization of prolactin-releasing peptide: binding, signaling and hormone secretion in rodent pituitary cell lines endogenously expressing its receptor. Maixnerová J; Špolcová A; Pýchová M; Blechová M; Elbert T; Rezáčová M; Zelezná B; Maletínská L Peptides; 2011 Apr; 32(4):811-7. PubMed ID: 21185342 [TBL] [Abstract][Full Text] [Related]
8. Mechanisms of cardiodepression by an Na+-H+ exchange inhibitor methyl-N-isobutyl amiloride (MIA) on the heart: lack of beneficial effects in ischemia-reperfusion injury. Saini HK; Elimban V; Ozcelikay AT; Dhalla NS Can J Physiol Pharmacol; 2007 Jan; 85(1):67-78. PubMed ID: 17487246 [TBL] [Abstract][Full Text] [Related]
9. Effects of a cardiotonic quinolinone derivative Y-20487 on the isoproterenol-induced positive inotropic action and cyclic AMP accumulation in rat ventricular myocardium: comparison with rolipram, Ro 20-1724, milrinone, and isobutylmethylxanthine. Katano Y; Endoh M J Cardiovasc Pharmacol; 1992; 20(5):715-22. PubMed ID: 1280732 [TBL] [Abstract][Full Text] [Related]
11. Phosphodiesterase inhibition by naloxone augments the inotropic actions of beta-adrenergic stimulation. Park WK; Chang CH; Chae JE; Kim MH; Cho YL; Ahn DS Acta Anaesthesiol Scand; 2009 Sep; 53(8):1043-51. PubMed ID: 19572940 [TBL] [Abstract][Full Text] [Related]
12. Positive inotropic, positive chronotropic and coronary vasodilatory effects of rat amylin: mechanisms of amylin-induced positive inotropy. Kaygisiz Z; Ozden H; Erkasap N; Koken T; Gunduz T; Ikizler M; Kural T Acta Physiol Hung; 2010 Dec; 97(4):362-74. PubMed ID: 21138812 [TBL] [Abstract][Full Text] [Related]
13. Stimulatory phosphorylation of cAMP-specific PDE4D5 by contractile agonists is mediated by PKC-dependent inactivation of protein phosphatase 2A. Murthy KS; Sriwai W Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G327-35. PubMed ID: 18006600 [TBL] [Abstract][Full Text] [Related]
14. Kinases and phosphatases in ischaemic preconditioning: a re-evaluation. Fan WJ; van Vuuren D; Genade S; Lochner A Basic Res Cardiol; 2010 Jul; 105(4):495-511. PubMed ID: 20127248 [TBL] [Abstract][Full Text] [Related]
15. Various inotropic effects of angiotensin II in post-ischaemic rat hearts depending on ischaemic time with possible involvement of protein kinase C. Wang QD; Nygren E Acta Physiol Scand; 2003 Jul; 178(3):189-96. PubMed ID: 12823176 [TBL] [Abstract][Full Text] [Related]
16. Diazepam enhances inotropic responses to dopamine in rat ventricular myocardium. Juan-Fita MJ; Vargas ML; Hernández J Anesth Analg; 2006 Mar; 102(3):676-81. PubMed ID: 16492814 [TBL] [Abstract][Full Text] [Related]
17. Prolactin-releasing peptide regulates the cardiovascular system via corticotrophin-releasing hormone. Yamada T; Mochiduki A; Sugimoto Y; Suzuki Y; Itoi K; Inoue K J Neuroendocrinol; 2009 Jun; 21(6):586-93. PubMed ID: 19500229 [TBL] [Abstract][Full Text] [Related]
18. Functionally opposing roles of extracellular signal-regulated kinase 1/2 and p38 mitogen-activated protein kinase in the regulation of cardiac contractility. Szokodi I; Kerkelä R; Kubin AM; Sármán B; Pikkarainen S; Kónyi A; Horváth IG; Papp L; Tóth M; Skoumal R; Ruskoaho H Circulation; 2008 Oct; 118(16):1651-8. PubMed ID: 18824646 [TBL] [Abstract][Full Text] [Related]
19. Participation of the prolactin-releasing peptide-containing neurones in caudal medulla in conveying haemorrhagic stress-induced signals to the paraventricular nucleus of the hypothalamus. Uchida K; Kobayashi D; Das G; Onaka T; Inoue K; Itoi K J Neuroendocrinol; 2010 Jan; 22(1):33-42. PubMed ID: 19912474 [TBL] [Abstract][Full Text] [Related]
20. Prolactin releasing peptide (PrRP) stimulates luteinizing hormone (LH) and follicle stimulating hormone (FSH) via a hypothalamic mechanism in male rats. Seal LJ; Small CJ; Kim MS; Stanley SA; Taheri S; Ghatei MA; Bloom SR Endocrinology; 2000 May; 141(5):1909-12. PubMed ID: 10803604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]